Effect of a Single Dose of Rituximab in Chronic Immune Thrombocytopenic Purpura in Childhood
Overview
Authors
Affiliations
Twenty-two children with immune thrombocytopenic purpura (ITP) with long-lasting thrombocytopenia, adversely affecting their quality of life, were treated with a reduced rituximab regimen in order to eliminate B cells producing anti-platelet antibody. A single dose of rituximab resulted in a response rate similar to that reported for cases in which 4 doses of rituximab were used.
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?.
Lucchini E, Zaja F, Bussel J Haematologica. 2019; 104(6):1124-1135.
PMID: 31126963 PMC: 6545833. DOI: 10.3324/haematol.2019.218883.
Tong H, Ye L, Ye X, Lu D, Li Y Exp Ther Med. 2015; 10(6):2295-2298.
PMID: 26668631 PMC: 4665988. DOI: 10.3892/etm.2015.2797.
Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.
Matsubara K, Takahashi Y, Hayakawa A, Tanaka F, Nakadate H, Sakai M Int J Hematol. 2014; 99(4):429-36.
PMID: 24609717 DOI: 10.1007/s12185-014-1541-y.
Rituximab for children with immune thrombocytopenia: a systematic review.
Liang Y, Zhang L, Gao J, Hu D, Ai Y PLoS One. 2012; 7(5):e36698.
PMID: 22666325 PMC: 3364261. DOI: 10.1371/journal.pone.0036698.
Patel V, Mahevas M, Lee S, Stasi R, Cunningham-Rundles S, Godeau B Blood. 2012; 119(25):5989-95.
PMID: 22566601 PMC: 3383014. DOI: 10.1182/blood-2011-11-393975.